Anna-Lena Wiessler

Anna-Lena Wiessler

Auto-generated profile, based on publicly available information

Anna-Lena Wiessler

Institute for Clinical Neurobiology University Hospital of Würzburg Würzburg Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
AWAnna-Lena Wiessler
Anna-Lena Wiessler
FZFang Zheng
Fang Zheng
CWChristian Werner
Christian Werner
MHMargarita Habib
Margarita Habib
ETErdem Tüzün
Erdem Tüzün
CVCarmen Villmann
Carmen Villmann
Autoantibodies (aAbs) against glycine receptors (GlyRs) are mainly associated with the rare neurologic diseases stiff person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM). GlyR aAbs are also found in other neurologic diseases such as epilepsy. The aAbs bind to different GlyR α-subunits and, more rarely, also to the GlyR β-subunit. So far, studies on the pathogenic effects of the aAbs have focused on postsynaptic, heteromeric GlyRs, reporting a loss of ion channel function and receptor internalization upon aAb binding. We asked whether the aAbs also affect expression and functionality of presynaptic homomeric GlyRs. We established interneuron cultures from mouse embryonic spinal cord neurons and used protein biochemistry and super-resolution microscopy to determine aAb binding to presynaptic GlyRs in a uniform neuronal subpopulation. Brainstem slice recordings were used to detect functional alterations. Several days-long exposure of spinal cord cultures with GlyR aAbs did not change expression levels of proteins building a functional glycinergic synapse. A notable exception was the enhanced expression of presynaptic glycine transporter 2 (GlyT2), possibly reflecting an adaptation to altered synaptic properties. Super-resolution microscopy revealed rather similar binding of patient-derived aAbs to postsynaptic vs presynaptic sites with individual binding preferences. Although characterization of interneurons showed absence of GlyRα1 in some interneuron subpopulations, GlyRα2 and patient serum signals exhibited a significantly higher colocalization in samples with presynaptic preference. This finding identifies GlyRα2 as the hitherto unknown predominant presynaptic GlyR subunit in the spinal cord and a target of patient aAbs. Whole-cell recordings from glycinergic neurons in mouse brainstem slices underscored the functional relevance of presynaptic aAb binding demonstrated by a significant reduction in the frequency of spontaneous and miniature inhibitory postsynaptic potentials. In summary, our study is the first to implicate presynaptic defects in the pathophysiology of autoimmune diseases such as SPS and PERM, which are associated with GlyR aAbs. Individually tuned binding preferences for presynaptic and postsynaptic targets thus underlie the rather diverse appearance of clinical symptoms and different therapeutic responses in patients suffering from GlyR autoimmunity.

1 July 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
MHMargarita Habib
Margarita Habib
AWAnna-Lena Wiessler
Anna-Lena Wiessler
PFPatrik Fischer
Patrik Fischer
MNMichele Niesner
Michele Niesner
MSMareike Selcho
Mareike Selcho
CVCarmen Villmann
Carmen Villmann
Patients with autoantibodies (aAbs) against the contactin-associated protein-like 2 (CASPR2) suffer from a variety of clinical syndromes including neuropathic pain. CASPR2 is an adhesion protein of the neurexin family and part of the voltage-gated potassium channel complex (VGKC complex) in dorsal root ganglia (DRG) neurons. The pathologic mechanisms following the binding of CASPR2 aAbs and their association with pain are only partially understood. CASPR2 aAbs are mainly of the IgG4 subclass; however, previous studies have neglected subclass-dependent effects. We investigated 49 subclassified patient serum samples positive for CASPR2 aAbs combining superresolution lattice structural illumination microscopy (SIM2) and functional readouts by calcium imaging and electrophysiologic recordings on cultured DRG neurons. CASPR2-positive patient sera subclassified in IgG4 together with at least 1 other IgG subclass (IgGX) and patients with only IgG4 were further subdivided into the pain and no pain groups. A decrease of CASPR2 expression along the axons after exposure to CASPR2 aAbs was observed for all patient groups except the group without pain and IgG4. Moreover, binding of CASPR2 aAbs from patients with pain increased the distance between CASPR2 and associated potassium channels along DRG axons determined by SIM2 microscopy. CASPR2 aAbs of patients with pain significantly increased overall neuronal excitability of cultured DRG neurons as measured by calcium imaging. Patch-clamp recordings revealed significantly decreased current amplitudes of voltage-gated potassium (Kv) channels after incubation with all 4 CASPR2 aAb subclassifications with the most prominent effect of serum samples harboring IgG4 aAbs only. Replacement of patient aAbs by healthy control serum rescued Kv channel function to normal levels suggesting that the affected potassium channel function is due to structural blockage and disrupted interactions within the VGKC complex. The last might also be rescued on novel protein synthesis and membrane trafficking of CASPR2. IgG4 aAbs seem to be the major modifier of potassium channel function. The DRG hyperexcitability is primarily due to impaired Kv channel conductance as a consequence of CASPR2 aAb binding. However, additional unidentified signal pathways contribute to this process in patients with neuropathic pain.

20 March 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
CHChristiane Huhn
Christiane Huhn
SHSheng-Yang Ho
Sheng-Yang Ho
CSClemens Schulte
Clemens Schulte
VKVladimir Khayenko
Vladimir Khayenko
KHKatherina Hemmen
Katherina Hemmen
HMHans Maric
Hans Maric

15 February 2026 in Advanced Healthcare Materials
Verified
Journal Article
Open access
NMNicoletta Murenu
Nicoletta Murenu
ETEsra Tuerker
Esra Tuerker
AWAnna‐Lena Wiessler
Anna‐Lena Wiessler
JFJessica Faber
Jessica Faber
ILIevgenii Liashenko
Ievgenii Liashenko
NSNatascha Schäfer
Natascha Schäfer
Three‐dimensional (3D) models to study human disease mechanisms have demonstrated that the third dimension is an essential component for neuronal maturation and function. However, 3D neuronal cell culture is challenging due to their ultra‐soft nature and specific extracellular matrix (ECM) organization. This study presents a microfiber reinforcement approach, combining primary mouse spinal cord neurons (SCNs) in a purpose‐adaptable hyaluronic‐acid‐based matrix with melt electrowritten (MEW) frames to study disease mechanisms. The importance of laminins (LNs) is evaluated, which are vital for neuronal adhesion and maturation. Astrocytes (ACs) are mandatory in brain development and function by secretion of signal molecules, maintaining ion homeostasis, clearing of neurotransmitters, and by actively modulating neuronal activity. Three combinations are compared (i) isolated primary SCN, (ii) SCN with ACs (SCN‐AC) and (iii) SCN‐AC and LNs (SCN‐AC‐LN). Multimodal analysis by comparing protein expression, dendrite length, complex mechanical properties, and network functionality via Ca 2+ ‐imaging allows validation of structural and functional neuronal network development. The suitability of the 3D model to study pathomechanisms is demonstrated for Stiff Person Syndrome (SPS). For the first time, functional impairment of spinal cord neurons by patient‐derived autoantibodies characteristic for SPS is recapitulated in a 3D spinal cord model platform adaptable to other disease types.

28 July 2025 in Phytomedicine Plus
Verified
Journal Article
Open access
CBChristian Böhm
Christian Böhm
AWAnna-Lena Wiessler
Anna-Lena Wiessler
DJDieter Janzen
Dieter Janzen
JNJulian Nausester
Julian Nausester
BSBenedikt Slavik
Benedikt Slavik
ABAndrea Buettner
Andrea Buettner

24 July 2026 in Scientific Reports
Verified
Journal Article
Open access
SFSean D. Fraser
Sean D. Fraser
AWAnna-Lena Wiessler
Anna-Lena Wiessler
WCWing Yan Jessica Choi
Wing Yan Jessica Choi
NSNatascha Schäfer
Natascha Schäfer
PSPatrick Sutton
Patrick Sutton
Robert HarveyRobert Harvey
Robert Harvey
Rare genetic variants in the glycine receptor (GlyR) α2 subunit gene ( GLRA2 ) are associated with autism spectrum disorder, developmental delay, and intellectual disability, often accompanied by microcephaly, language delay or epilepsy. We report detailed structure-function analyses of nine previously uncharacterised GlyR α2 missense variants, including a novel de novo change (p.S285P) linked to epileptic encephalopathy. Using molecular modelling/dynamics simulations, electrophysiology, and immunocytochemistry, we assessed effects of GlyR α2 variants on agonist potency, efficacy, channel gating, and cell-surface trafficking. Five missense variants caused a partial loss-of-function via reduced glycine potency (p.F20S, p.A261T, p.R418Q), reduced glycine efficacy (p.F20S), or faster channel deactivation (p.R323C, p.P369T). By contrast, p.R225C abolished cell-surface expression resulting in a complete loss-of-function . The p.A261T variant also significantly reduced picrotoxin binding, resolving ambiguity in GlyR-PTX interaction models. Additional variants showed an alteration-of-function (p.I232M) or a gain-of-function (p.S285P), combining reduced glycine efficacy with increased potency and spontaneous leak currents. Two variants within the intracellular M3-M4 domain (p.R323C and p.P369T) had enhanced channel deactivation consistent with a loss-of-function , while p.P373L showed no detectable functional deficit. These findings expand the clinical and mechanistic spectrum of GlyR α2 variants, identify a key determinant of picrotoxin binding, and highlight unresolved roles of intracellular protein-protein interaction motifs in GlyR α2 function.